#3

OIPE

RAW SEQUENCE LISTING DATE: 02/15/2002
PATENT APPLICATION: **US/10/058,821** TIME: 15:27:36

Input Set : **A:\401c12.app**
Output Set: **N:\CRF3\02152002\J058821.raw**

```
      3 <110> APPLICANT: Blaschuk, Orest W.
      4       Gour, Barbara J.
      5       Farookhi, Riaz
      7 <120> TITLE OF INVENTION: COMPOUNDS AND METHODS FOR CANCER THERAPY
      9 <130> FILE REFERENCE: 100086.401C12
C--> 11 <140> CURRENT APPLICATION NUMBER: US/10/058,821
     12 <141> CURRENT FILING DATE: 2002-01-29
     14 <160> NUMBER OF SEQ ID NOS: 58
     16 <170> SOFTWARE: PatentIn Ver. 2.0
     18 <210> SEQ ID NO: 1
     19 <211> LENGTH: 108
     20 <212> TYPE: PRT
     21 <213> ORGANISM: Homo sapiens
     23 <400> SEQUENCE: 1
     24 Asp Trp Val Ile Pro Pro Ile Asn Leu Pro Glu Asn Ser Arg Gly Pro
     25   1               5                  10                  15
     27 Phe Pro Gln Glu Leu Val Arg Ile Arg Ser Asp Arg Asp Lys Asn Leu
     28              20                  25                  30
     30 Ser Leu Arg Tyr Ser Val Thr Gly Pro Gly Ala Asp Gln Pro Pro Thr
     31          35                  40                  45
     33 Gly Ile Phe Ile Leu Asn Pro Ile Ser Gly Gln Leu Ser Val Thr Lys
     34      50                  55                  60
     36 Pro Leu Asp Arg Glu Gln Ile Ala Arg Phe His Leu Arg Ala His Ala
     37  65                  70                  75                  80
     39 Val Asp Ile Asn Gly Asn Gln Val Glu Asn Pro Ile Asp Ile Val Ile
     40                  85                  90                  95
     42 Asn Val Ile Asp Met Asn Asp Asn Arg Pro Glu Phe
     43             100                 105
     46 <210> SEQ ID NO: 2
     47 <211> LENGTH: 108
     48 <212> TYPE: PRT
     49 <213> ORGANISM: Mus musculus
     51 <400> SEQUENCE: 2
     52 Asp Trp Val Ile Pro Pro Ile Asn Leu Pro Glu Asn Ser Arg Gly Pro
     53   1               5                  10                  15
     55 Phe Pro Gln Glu Leu Val Arg Ile Arg Ser Asp Arg Asp Lys Asn Leu
     56              20                  25                  30
     58 Ser Leu Arg Tyr Ser Val Thr Gly Pro Gly Ala Asp Gln Pro Pro Thr
     59          35                  40                  45
     61 Gly Ile Phe Ile Ile Asn Pro Ile Ser Gly Gln Leu Ser Val Thr Lys
     62      50                  55                  60
     64 Pro Leu Asp Arg Glu Leu Ile Ala Arg Phe His Leu Arg Ala His Ala
     65  65                  70                  75                  80
```

ENTERED

RAW SEQUENCE LISTING DATE: 02/15/2002
PATENT APPLICATION: US/10/058,821 TIME: 15:27:36

Input Set : A:\401c12.app
Output Set: N:\CRF3\02152002\J058821.raw

```
67 Val Asp Ile Asn Gly Asn Gln Val Glu Asn Pro Ile Asp Ile Val Ile
68                  85                  90                  95
70 Asn Val Ile Asp Met Asn Asp Asn Arg Pro Glu Phe
71             100                 105
74 <210> SEQ ID NO: 3
75 <211> LENGTH: 108
76 <212> TYPE: PRT
77 <213> ORGANISM: Bos taurus
79 <400> SEQUENCE: 3
80 Asp Trp Val Ile Pro Pro Ile Asn Leu Pro Glu Asn Ser Arg Gly Pro
81   1               5                  10                  15
83 Phe Pro Gln Glu Leu Val Arg Ile Arg Ser Asp Arg Asp Lys Asn Leu
84              20                  25                  30
86 Ser Leu Arg Tyr Ser Val Thr Gly Pro Gly Ala Asp Gln Pro Pro Thr
87          35                  40                  45
89 Gly Ile Phe Ile Ile Asn Pro Ile Ser Gly Gln Leu Ser Val Thr Lys
90      50                  55                  60
92 Pro Leu Asp Arg Glu Leu Ile Ala Arg Phe His Leu Arg Ala His Ala
93  65                  70                  75                  80
95 Val Asp Ile Asn Gly Asn Gln Val Glu Asn Pro Ile Asp Ile Val Ile
96                  85                  90                  95
98 Asn Val Ile Asp Met Asn Asp Asn Arg Pro Glu Phe
99             100                 105
102 <210> SEQ ID NO: 4
103 <211> LENGTH: 108
104 <212> TYPE: PRT
105 <213> ORGANISM: Homo sapiens
107 <400> SEQUENCE: 4
108 Asp Trp Val Val Ala Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro
109   1               5                  10                  15
111 Phe Pro Gln Arg Leu Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr
112              20                  25                  30
114 Lys Ile Phe Tyr Ser Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu
115          35                  40                  45
117 Gly Val Phe Ala Val Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys
118      50                  55                  60
120 Pro Leu Asp Arg Glu Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala
121  65                  70                  75                  80
123 Val Ser Glu Asn Gly Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile
124                 85                  90                  95
126 Ile Val Thr Asp Gln Asn Asp His Lys Pro Lys Phe
127             100                 105
130 <210> SEQ ID NO: 5
131 <211> LENGTH: 108
132 <212> TYPE: PRT
133 <213> ORGANISM: Mus musculus
135 <400> SEQUENCE: 5
136 Glu Trp Val Met Pro Pro Ile Phe Val Pro Glu Asn Gly Lys Gly Pro
137   1               5                  10                  15
```

RAW SEQUENCE LISTING DATE: 02/15/2002
PATENT APPLICATION: US/10/058,821 TIME: 15:27:36

Input Set : A:\401c12.app
Output Set: N:\CRF3\02152002\J058821.raw

```
139 Phe Pro Gln Arg Leu Asn Gln Leu Lys Ser Asn Lys Asp Arg Gly Thr
140              20                  25                  30
142 Lys Ile Phe Tyr Ser Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu
143          35                  40                  45
145 Gly Val Phe Thr Ile Glu Lys Glu Ser Gly Trp Leu Leu Leu His Met
146      50                  55                  60
148 Pro Leu Asp Arg Glu Lys Ile Val Lys Tyr Glu Leu Tyr Gly His Ala
149  65                  70                  75                  80
151 Val Ser Glu Asn Gly Ala Ser Val Glu Glu Pro Met Asn Ile Ser Ile
152                  85                  90                  95
154 Ile Val Thr Asp Gln Asn Asp Asn Lys Pro Lys Phe
155              100                 105
158 <210> SEQ ID NO: 6
159 <211> LENGTH: 108
160 <212> TYPE: PRT
161 <213> ORGANISM: Homo sapiens
163 <400> SEQUENCE: 6
164 Asp Trp Val Ile Pro Pro Ile Ser Cys Pro Glu Asn Glu Lys Gly Pro
165   1               5                  10                  15
167 Phe Pro Lys Asn Leu Val Gln Ile Lys Ser Asn Lys Asp Lys Glu Gly
168              20                  25                  30
170 Lys Val Phe Tyr Ser Ile Thr Gly Gln Gly Ala Asp Thr Pro Pro Val
171          35                  40                  45
173 Gly Val Phe Ile Ile Glu Arg Glu Thr Gly Trp Leu Lys Val Thr Glu
174      50                  55                  60
176 Pro Leu Asp Arg Glu Arg Ile Ala Thr Tyr Thr Leu Phe Ser His Ala
177  65                  70                  75                  80
179 Val Ser Ser Asn Gly Asn Ala Val Glu Asp Pro Met Glu Ile Leu Ile
180                  85                  90                  95
182 Thr Val Thr Asp Gln Asn Asp Asn Lys Pro Glu Phe
183              100                 105
186 <210> SEQ ID NO: 7
187 <211> LENGTH: 108
188 <212> TYPE: PRT
189 <213> ORGANISM: Mus musculus
191 <400> SEQUENCE: 7
192 Asp Trp Val Ile Pro Pro Ile Ser Cys Pro Glu Asn Glu Lys Gly Glu
193   1               5                  10                  15
195 Phe Pro Lys Asn Leu Val Gln Ile Lys Ser Asn Arg Asp Lys Glu Thr
196              20                  25                  30
198 Lys Val Phe Tyr Ser Ile Thr Gly Gln Gly Ala Asp Lys Pro Pro Val
199          35                  40                  45
201 Gly Val Phe Ile Ile Glu Arg Glu Thr Gly Trp Leu Lys Val Thr Gln
202      50                  55                  60
204 Pro Leu Asp Arg Glu Ala Ile Ala Lys Tyr Ile Leu Tyr Ser His Ala
205  65                  70                  75                  80
207 Val Ser Ser Asn Gly Glu Ala Val Glu Asp Pro Met Glu Ile Val Ile
208                  85                  90                  95
210 Thr Val Thr Asp Gln Asn Asp Asn Arg Pro Glu Phe
```

RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/058,821

DATE: 02/15/2002
TIME: 15:27:36

Input Set : A:\401c12.app
Output Set: N:\CRF3\02152002\J058821.raw

```
211              100                 105
214 <210> SEQ ID NO: 8
215 <211> LENGTH: 5
216 <212> TYPE: PRT
217 <213> ORGANISM: Unknown
219 <220> FEATURE:
220 <221> NAME/KEY: MOD_RES
221 <222> LOCATION: (2)
222 <223> OTHER INFORMATION: Where Xaa is any amino acid
224 <220> FEATURE:
225 <223> OTHER INFORMATION: Description of Unknown Organism: Cadherin Calcium
226       Binding Motif
228 <400> SEQUENCE: 8
229 Asp Xaa Asn Asp Asn
230   1               5
233 <210> SEQ ID NO: 9
234 <211> LENGTH: 4
235 <212> TYPE: PRT
236 <213> ORGANISM: Unknown
238 <220> FEATURE:
239 <223> OTHER INFORMATION: Description of Unknown Organism: Cadherin Calcium
240       Binding Motif
242 <400> SEQUENCE: 9
243 Leu Asp Arg Glu
244   1
247 <210> SEQ ID NO: 10
248 <211> LENGTH: 5
249 <212> TYPE: PRT
250 <213> ORGANISM: Artificial Sequence
252 <220> FEATURE:
253 <223> OTHER INFORMATION: Description of Artificial Sequence: Cyclic Peptide
254       with Classical Cell Adhesion Recognition Sequence
256 <220> FEATURE:
257 <223> OTHER INFORMATION: Cyclic Peptide may comprise N-terminal
258       modification such as acetyl or alkoxybenzyl group
259       and/or C-terminal modifications such as amide or
260       ester group
262 <400> SEQUENCE: 10
263 Cys His Ala Val Cys
264   1               5
267 <210> SEQ ID NO: 11
268 <211> LENGTH: 5
269 <212> TYPE: PRT
270 <213> ORGANISM: Artificial Sequence
272 <220> FEATURE:
273 <223> OTHER INFORMATION: Description of Artificial Sequence: Cyclic
274       control peptide
276 <220> FEATURE:
277 <223> OTHER INFORMATION: Cyclic Peptide may comprise N-terminal
```

RAW SEQUENCE LISTING DATE: 02/15/2002
PATENT APPLICATION: US/10/058,821 TIME: 15:27:36

Input Set : A:\401c12.app
Output Set: N:\CRF3\02152002\J058821.raw

```
278       modification such as acetyl or alkoxybenzyl group
279       and/or C-terminal modifications such as amide or
280       ester group
282 <400> SEQUENCE: 11
283 Cys His Gly Val Cys
284   1               5
287 <210> SEQ ID NO: 12
288 <211> LENGTH: 5
289 <212> TYPE: PRT
290 <213> ORGANISM: Artificial Sequence
292 <220> FEATURE:
293 <223> OTHER INFORMATION: Description of Artificial Sequence: Cyclic
294       peptide with cadherin cell adhesion recognition
295       sequence
297 <220> FEATURE:
298 <223> OTHER INFORMATION: Cyclic Peptide may comprise N-terminal
299       modification such as acetyl or alkoxybenzyl group
300       and/or C-terminal modifications such as amide or
301       ester group
303 <400> SEQUENCE: 12
304 Lys His Ala Val Asp
305   1               5
307 <210> SEQ ID NO: 13
308 <211> LENGTH: 5
309 <212> TYPE: PRT
310 <213> ORGANISM: Artificial Sequence
312 <220> FEATURE:
313 <223> OTHER INFORMATION: Description of Artificial Sequence: Cyclic
314       peptide with cadherin cell adhesion recognition
315       sequence
317 <220> FEATURE:
318 <223> OTHER INFORMATION: Cyclic Peptide may comprise N-terminal
319       modification such as acetyl or alkoxybenzyl group
320       and/or C-terminal modifications such as amide or
321       ester group
323 <400> SEQUENCE: 13
324 Asp His Ala Val Lys
325   1               5
328 <210> SEQ ID NO: 14
329 <211> LENGTH: 5
330 <212> TYPE: PRT
331 <213> ORGANISM: Artificial Sequence
333 <220> FEATURE:
334 <223> OTHER INFORMATION: Description of Artificial Sequence: Cyclic
335       peptide with classical cadherin cell adhesion
336       recognition sequence
338 <220> FEATURE:
339 <223> OTHER INFORMATION: Cyclic Peptide may comprise N-terminal
340       modification such as acetyl or alkoxybenzyl group
```

Use of n and/or Xaa has been detected in the Sequence Listing.
Please review the Sequence Listing to insure a corresponding explanation is presented in the <220> to <223> fields of each sequence using n or Xaa.

VERIFICATION SUMMARY
PATENT APPLICATION: US/10/058,821

DATE: 02/15/2002
TIME: 15:27:37

Input Set : A:\401c12.app
Output Set: N:\CRF3\02152002\J058821.raw

L:11 M:270 C: Current Application Number differs, Wrong Format
L:229 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8
L:789 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:36
L:837 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:37
L:1072 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47
L:1098 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48
L:1124 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:49
L:1150 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:50
L:1178 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:51